无创诊断肝硬化门静脉高压症:血清标志物还是影像学检查？

doi:10.3969/j.issn.1672-5069.2022.01.003

Abstract

Chen Jing, Zhu Yueyong. Non-invasive diagnosis of portal hypertension in patients with liver cirrhosis: serum markers or imaging?[J]. Journal of Practical Hepatology, 2022, 25(1): 9-12.

[1] Simbrunner B,Marculescu R,Scheiner B,et al.Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different etiologies of advanced chronic liver disease.Liver Int,2020,40(7):1713-1724.
[2] Sandahl TD,McGrail R,Moller HJ,et al.The macrophage activation marker sCD163 combined with markers of the enhanced liver fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis. Aliment Pharmacol Ther,2016,43(11):1222-1231.
[3] Wang L,Feng Y,Ma X,et al.Diagnostic efficacy of noninvasive liver fibrosis indexes in predicting portal hypertension in patients with cirrhosis.Plos One,2017,12(8):e0182969.
[4] Ferlitsch M,Reiberger T,Hoke M,et al.von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.Hepatology,2012,56(4):1439-1447.
[5] Maieron A,Salzl P,Peck-Radosavljevic M,et al.von Willebrand factor as a new marker for non-invasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis C.Aliment Pharmacol Therapeut,2014,39(3):331-338.
[6] Hametner S,Ferlitsch A,Ferlitsch M, et al.The VITRO score (von Willebrand factor antigen/thrombocyte ratio) as a new marker for clinically significant portal hypertension in comparison to other non-invasive parameters of fibrosis including ELF test.Plos One,2016,11(2):e0149230.
[7] Langholm LL,Manon-Jensen T,Karsdal MA,et al.Enhanced processing of von Willebrand factor reflects disease severity and discriminates severe portal hypertension in cirrhosis.Eur J Gastroenterol Hepatol,2019,31(8):1040-1048.
[8] Kim MY,Suk KT,Baik SK,et al.Hepatic vein arrival time as assessed by contrast-enhanced ultrasonography is useful for the assessment of portal hypertension in compensated cirrhosis.Hepatology,2012,56(3):1053-1062.
[9] Shimada T,Maruyama H,Kondo T,et al.Impact of splenic circulation:non-invasive microbubble-based assessment of portal hemodynamics.Eur Radiol,2015,25(3):812-820.
[10] Gupta I,Eisenbrey JR,Machado P,et al.Diagnosing portal hypertension with noninvasive subharmonic pressure estimates from a US contrast agent.Radiology,2021,298(1):104-111.
[11] Maruyama H,Yokosuka O.Ultrasonography for noninvasive assessment of portal hypertension.Gut Liver,2017,11(4):464-473.
[12] Thiele M,Hugger MB,Kim Y,et al.2D shear wave liver elastography by Aixplorer to detect portal hypertension in cirrhosis:An individual patient data meta-analysis.Liver Int,2020,40(6):1435-1446.
[13] Hu X,Huang X,Hou J,et al.Diagnostic accuracy of spleen stiffness to evaluate portal hypertension and esophageal varices in chronic liver disease:a systematic review and meta-analysis.Eur Radiol,2021,31(4):2392-2404.
[14] Sartoris R,Rautou PE,Elkrief L,et al.Quantification of liver surface nodularity at CT:utility for detection of portal hypertension.Radiology,2018,289(3):698-707.
[15] Sartoris R,Lazareth M,Nivolli A,et al.CT-based liver surface nodularity for the detection of clinically significant portal hypertension: defining measurement quality criteria.Abdom Radiol (NY),2020,45(9):2755-2763.
[16] Bane O,Peti S,Wagner M,et al.Hemodynamic measurements with an abdominal 4D flow MRI sequence with spiral sampling and compressed sensing in patients with chronic liver disease.J Magnet Reson Imaging,2019,49(4):994-1005.
[17] Mesropyan N,Isaak A,Faron A,et al.Magnetic resonance parametric mapping of the spleen for non-invasive assessment of portal hypertension.Eur Radiol,2021,31(1):85-93.
[18] Hectors SJ,Bane O,Kennedy P,et al.Noninvasive diagnosis of portal hypertension using gadoxetate DCE-MRI of the liver and spleen.Eur Radiol,2021,31(7):4804-4812.
[19] Ronot M,Lambert S,Elkrief L,et al.Assessment of portal hypertension and high-risk oesophageal varices with liver and spleen three-dimensional multifrequency MR elastography in liver cirrhosis.Eur Radiol,2014,24(6):1394-1402.
[20] Wagner M,Hectors S,Bane O,et al.Noninvasive prediction of portal pressure with MR elastography and DCE-MRI of the liver and spleen:Preliminary results.J Magnet Reson Imaging,2018,48(4):1091-1103.

Non-invasive diagnosis of portal hypertension in patients with liver cirrhosis: serum markers or imaging?

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zeng Yi, Li Guo, Li Hongcui, et al. Efficacy of ursodeoxycholic acid in the treatment of patients with primary biliary cholangitis and cirrhosis and its effect on serum Nrf2 and HO-1 levels [J]. Journal of Practical Hepatology, 2022, 25(2): 211-214.
[2]	Hao Yuting, Lin Jie, Qin Jie. Clinical implication of serum aquaporin-8 and aquaporin-9 in patients with hepatitis B-induced liver cirrhosis receiving long-term entecavir therapy [J]. Journal of Practical Hepatology, 2022, 25(2): 243-246.
[3]	Wang Benxian, Li Wei, Li Dongsheng, et al. Cell-free and concentrated ascites reinfusion therapy for patients with decompensated cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(2): 247-250.
[4]	He Fuliang, Ma Lin, Li Yuerong, et al. Non-cirrhotic portal hypertension:the highlight of its diagnosis [J]. Journal of Practical Hepatology, 2022, 25(1): 1-4.
[5]	Zhang Yu, Liu Fuquan. Precision technique and rational shunt in transjugular intrahepatic portosystemic shunt [J]. Journal of Practical Hepatology, 2022, 25(1): 5-8.
[6]	Li Yanle, Liu Xiaoyu, Yao Jianning, et al. Serum ammonia level changes and its correlation to cognitive impairment in patients with hepatitis B cirrhosis and hepatic encephalopathy [J]. Journal of Practical Hepatology, 2022, 25(1): 74-78.
[7]	Wang Jing, Bi Ning, Fang Liang, et al. Correlation of blood CD64 index to intestinal mucosal barrier functions in patients with hepatitis B cirrhosis and spontaneous bacterial peritonitis [J]. Journal of Practical Hepatology, 2022, 25(1): 79-82.
[8]	Wu Ling, Li Feng. Administration of non-selective beta-blockers in treatment of patients with liver cirrhosis and portal hypertension [J]. Journal of Practical Hepatology, 2022, 25(1): 144-147.
[9]	Shi Cuicui, Liu Yanjun, Zhang Ruinan, et al. Dyslipidemia in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 859-862.
[10]	Liu Mei, Shi Yonghong, Ying Juan, et al. Prevalence of nosocomial infection and resistance of pathogens in patients with decompensated liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 863-866.
[11]	Liu Yuling, Zhen Zengguo, Wang Huijuan, et al. Effects of probiotics on intestinal barrier function of patients with liver cirrhosis complicated by spontaneous bacterial peritonitis [J]. Journal of Practical Hepatology, 2021, 24(6): 867-870.
[12]	Xing Li, Du Qianying, Jiang Yanli, et al. Impact of segmented injection of contrast agent on hepatic vein imaging by CT angiography in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 871-874.
[13]	Huang Liou, Wu Chunrong, Xu Dan, et al. Efficacy of continuous renal replacement therapy without heparinization in patients with liver cirrhosis complicated by hepatic encephalopathy [J]. Journal of Practical Hepatology, 2021, 24(6): 875-878.
[14]	Ye Dong, Zhang Junxia, LiJie, et al. Risk factors of rebleeding in hepatitis B liver cirrhotics with esophageal varices bleeding after endoscopic variceal ligation [J]. Journal of Practical Hepatology, 2021, 24(6): 879-882.
[15]	Han Chengmei, Han Yongfeng, Wang Chunhua. Risk factors for acute kidney injury in patients with hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 883-886.